Safety Study for Patients With a History of Hepatic Encephalopathy

This study has been completed.
Information provided by:
Valeant Pharmaceuticals International, Inc. Identifier:
First received: May 27, 2008
Last updated: February 2, 2011
Last verified: February 2011
This study will look at the safety of a drug used in patients who have had hepatic encephalopathy in the past.

Condition Intervention Phase
Hepatic Encephalopathy
Drug: rifaximin
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention

Resource links provided by NLM:

Further study details as provided by Valeant Pharmaceuticals International, Inc.:

Primary Outcome Measures:
  • Incidence of treatment-emergent AEs and SAEs [ Time Frame: Entire study ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Changes in laboratory values, vital signs, and HE parameters [ Time Frame: Entire study ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 500
Study Start Date: March 2007
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Open-label safety arm
Drug: rifaximin


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Must sign an Informed Consent Form
  • In remission from past hepatic encephalopathy (HE).
  • Appropriate birth control measures
  • More than or equal to 18 years of age.
  • Must be potential for benefit from treatment.
  • Recent HE episodes
  • Capable and willing to comply with all study procedures.
  • Subject has support network.

Exclusion Criteria:

  • Significant medical conditions or Investigator decision not to include.
  • Allergies to the study drug or similar drugs.
  • Laboratory abnormalities.
  • Recent participation in another clinical trial
  • Problems experienced in a previous HE trial.
  • Pregnant or at risk of pregnancy.
  • Recent alcohol consumption
  • Active or latent bacterial or viral Infections
  • Bowel issues
  • Recent Active Cancer
  • On a prohibited medication
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00686920

  Show 35 Study Locations
Sponsors and Collaborators
Valeant Pharmaceuticals International, Inc.
  More Information

No publications provided by Valeant Pharmaceuticals International, Inc.

Additional publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Michelle Widmann, Salix Pharmaceuticals Identifier: NCT00686920     History of Changes
Other Study ID Numbers: RFHE3002
Study First Received: May 27, 2008
Last Updated: February 2, 2011
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Hepatic Encephalopathy
Brain Diseases
Brain Diseases, Metabolic
Central Nervous System Diseases
Digestive System Diseases
Hepatic Insufficiency
Liver Diseases
Liver Failure
Metabolic Diseases
Nervous System Diseases processed this record on November 27, 2015